BIOSECURE Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill bars executive agencies, federal contractors, and federal loan or grant recipients from procuring or using biotechnology equipment or services from a biotechnology company of concern.
Who Benefits and How
Biotechnology providers that are not companies of concern, especially domestic or allied suppliers, could gain an advantage in federal procurement and federally funded work.
Who Bears the Burden and How
Executive agencies, contractors, and funding recipients would need to avoid covered biotechnology providers and monitor subcontracting and grant-funded use of those products and services.
Key Provisions
- Bars executive agencies from procuring biotechnology equipment or services from a biotechnology company of concern.
- Bars contracts with entities that use covered biotechnology equipment or services in performing federal contracts.
- Bars use of federal loan and grant funds to procure, obtain, or use covered biotechnology equipment or services.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
This bill bars executive agencies, federal contractors, and federal loan or grant recipients from procuring or using biotechnology equipment or services from a biotechnology company of concern.
Key Policy Areas
National Security, Healthcare
Primary Purpose
This bill bars executive agencies, federal contractors, and federal loan or grant recipients from procuring or using biotechnology equipment or services from a biotechnology company of concern.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Biotechnology providers that are not designated companies of concern
- Federal national security and supply-chain screening efforts
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Biotechnology companies of concern and entities that use their equipment or services in federally funded work
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeRead twice and referred to the Committee on Homeland Security …
Introduced in Senate
Mr. Peters (for himself and Mr. Hagerty) introduced the following …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Biotechnology companies of concern excluded from federal procurement and federally funded work
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology